Arcturus Therapeutics interim ARCT-810 Phase 2 shows biomarker improvements; unveils LUNAR 2.0, plans ARCT-2601 integration
Arcturus Therapeutics reported interim Phase 2 ARCT-810 data showing improved ammonia and glutamine biomarkers and unveiled LUNAR 2.0 with >30-fold higher protein expression.Key Highlights:Original SEC Filing: Arcturus Therapeutics Holdings Inc. [ ARCT ] - 8-K - Sep. 23, 2026This is an AI-powered s…